Simone Botti

Lundbeckfond Invest A/S (Lundbeckfond Invest) is the investment management subsidiary of the Lundbeck Foundation in Denmark. Established in 1999, the firm is based in Copenhagen and manages the Lundbeck Foundation's investments, aiming for long-term, stable returns with moderate risk, such that the Foundation's net capital is not jeopardized and the Foundation is able to meet its commitments in terms of awarding grants and of laying a capital base for its subsidiaries.

Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark.

Aveni SA designs, develops, manufactures and markets chemical formulations. It enables future technologies with its approach to metallization for semiconductor, MEMS, advanced packaging, and flex applications. The company was founded in 2001 and is headquartered in Massy, France.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom.

Melanoma Therapeutics Foundation supports and researches treatments for melanoma. It provides resources for patients and physicians, supports investigators, and provides new drug development through bridging relationships between academia, pharmaceutical and biotechnology companies. The foundation is headquartered in San Francisco, California

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

Holland Private Equity BV is a private equity and venture capital firm. The firm was founded in 2008 by Tim van Delden and Hans van Ierland. It’s headquartered in Amsterdam, the Netherlands.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

Niels Clauson-Kaas A/S provides research and experimental development services in the fields of natural sciences and engineering.

Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

MedAware Ltd. develops a software platform for the medical prescription market. Its software platform integrated with the electronic health record that detects the likelihood of a medication error. The firm offers alerting and risk management decision support tools. The company was founded by Gidi Stein and Tuvik Beker in 2012 and is headquartered in Raanana, Israel.

ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland.

EclecticIQ BV develops cyber threat intelligence platform. The company was founded by Joep Gommers and Raymon van der Velder in 2014 and is headquartered in Amsterdam, the Netherlands.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

Ciwit BV provides electronic data capture platform for medical research. The company was founded by Derk Arts in 2011 and is headquartered in Amsterdam, the Netherlands.

Luciole Medical AG operates as a Swiss medical technology company developing brain oxygenation monitoring systems. The firm's products include Rheopatch, RheoSens, RheoLity and RheoControl. The company was founded in September 2017 and is headquartered in Zurich, Switzerland.

LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023.

Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker.

Castor is a clinical data management company based in New York, NY. Castor provides a range of electronic solutions for clinical trials, including EDC, ePRO, eCOA, IWRS, CDMS, and decentralized trial solutions, all on a single platform. The company was founded by Derk Arts, who has been the CEO since incorporation.